SCM
TVRD

Silvant Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Silvant Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-253
Closed -$110K – 340
2022
Q1 		$110K Hold
253
– – 0.02% 219
2021
Q4 		$111K Sell
253
-16
-6% -$8.04K 0.02% 216
2021
Q3 		$149K Hold
269
– – 0.03% 205
2021
Q2 		$138K Hold
269
– – 0.02% 213
2021
Q1 		$210K Buy
+269
New +$184K 0.04% 181

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silvant Capital Management's TVRD Position: Q2 2022 in Review

Silvant Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2022, closing a stake of 253 shares — an estimated $110K sold.

Silvant Capital Management first reported a position in TVRD in Q1 2021 and held it in 5 quarters. The position peaked at $210K in Q1 2021. 179 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

  • Silvant Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Silvant Capital Management sold 253 Tvardi Therapeutics shares in Q2 2022, an estimated $110K.
  • Silvant Capital Management first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 5 quarters.
  • Silvant Capital Management's Tvardi Therapeutics position peaked at $210K in Q1 2021.
  • 179 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Silvant Capital Management's 13F filing for Q2 2022, filed 3 Aug 2022.